[CAS NO. 478336-92-4] ISO-1
PRODUCTS SPECIFICATIONS [478336-92-4]
DESCRIPTION [478336-92-4]
Overview
| MDL | MFCD22376813 |
|---|---|
| Molecular Weight | 235.24 |
| Molecular Formula | C12H13NO4 |
| SMILES | O=C(OC)CC1ON=C(C(C=C2)=CC=C2O)C1 |
5 Publications Citing Use of MCE
Summary
ISO-1 is a macrophage migration inhibitory factor ( MIF ) antagonist with an IC 50 of 7 μM.
IC50 & Target
IC50: 7 μM (MIF) [1]
In Vitro
ISO-1 (0.1-20 μM; 16 hours) has a slight inhibitory effect on Cox-2 secretion without the addition of recombinant MIF [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Western Blot Analysis [1]
| Cell Line: | RAW 264.7 macrophage cells |
| Concentration: | 0.1μM，1μM，10μM，20μM |
| Incubation Time: | 16 hours |
| Result: | Suppressed Cox-2 secretion. |
In Vivo
ISO-1 (injected intraperitoneally; 3.5-35 mg/kg; twice daily; 2 weeks) improves the survival rate from lethal endotoxemia and shows the anti-inflammatory effect
[2]
.
ISO-1 (intraperitoneal injection; 35 mg/kg; twice daily; 3 days) causes a significant reduction in average implant size and decreases Flk1 expression in implants
[3]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | C57Bl/6 MIF +/+ and MIF –/– mice [2] |
| Dosage: | 3.5-35 mg/kg |
| Administration: | Injected intraperitoneally; 3.5-35 mg/kg; twice a day ; 2 weeks |
| Result: | Was protective against lethal sepsis. |
| Animal Model: | Female C57BL/6-Tg(ACTB-EGFP)1Osb/J mice [3] |
| Dosage: | 35 mg/kg |
| Administration: | Intraperitoneal injection; 35 mg/kg; twice daily; 3 days |
| Result: | Reduced average endometriotic implant size. |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 50 mg/mL ( 212.55 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 4.2510 mL | 21.2549 mL | 42.5098 mL |
| 5 mM | 0.8502 mL | 4.2510 mL | 8.5020 mL |
| 10 mM | 0.4251 mL | 2.1255 mL | 4.2510 mL |
References
- [1] Lubetsky JB, et al. The tautomerase active site of macrophage migration inhibitory factor is a potential target for discovery of novel anti-inflammatory agents. J Biol Chem. 2002 Jul 12;277(28):24976-82.
- [2] Al-Abed Y, et al. ISO-1 binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severe sepsis. J Biol Chem. 2005 Nov 4;280(44):36541-4.
- [3] Nothnick WB, et al. Inhibition of macrophage migration inhibitory factor reduces endometriotic implant size in mice with experimentally induced disease. J Endometr. 2011 Sep 30;3(3):135-142.